Biotech Humacyte's Q3 net income beats expectations as Symvess sales rise

Humacyte

12/11/2025 12:13

Overview

Humacyte Q3 net income beats analyst expectations, despite a slight miss in operating income

Company's Q3 revenue increased significantly due to Symvess sales

Outlook

Humacyte plans supplemental BLA filing for ATEV dialysis indication in second half of 2026

Company aims to start first-in-human CTEV study for CABG in 2026

Humacyte expands intellectual property with new patent for bioengineered esophagus

Result Drivers

SYMVESS SALES GROWTH - Significant increase in Symvess sales driven by hospital approvals and inclusion in U.S. Defense Logistics Agency’s ECAT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Beat
-$17.51 mln
-$25.13 mln (6 Analysts)
Q3 Operating Income
Slight Miss*
-$24.39 mln
-$24.27 mln (6 Analysts)
Q3 Basic EPS
-$0.11
Q3 Operating Expenses
$25.14 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Humacyte Inc is $3.50, about 63.4% above its November 11 closing price of $1.28

Press Release: ID:nGNX54t6bm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)